Role of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-6 in the control of malignant pleural effusion and survival in patients with primary lung adenocarcinoma
Autor: | Li-Ke Yu, Qian Qian, Ping Zhan, Yu Zhang, Yong Song, Wen-Kui Sun |
---|---|
Rok vydání: | 2012 |
Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Pleural effusion Clinical Biochemistry Adenocarcinoma of Lung Kaplan-Meier Estimate Adenocarcinoma Disease-Free Survival Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Malignant pleural effusion Survival analysis Aged Lung Interleukin-6 Tumor Necrosis Factor-alpha business.industry Surrogate endpoint Hazard ratio Odds ratio Middle Aged medicine.disease Survival Analysis Pleural Effusion Malignant 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Female business |
Zdroj: | The International Journal of Biological Markers. 27:118-124 |
ISSN: | 1724-6008 |
Popis: | This study aimed at assessing the role of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the control of pleural effusion (PE) and survival in patients with primary lung adenocarcinoma. The concentrations of the 3 cytokines were measured in PE from 79 lung adenocarcinoma patients with malignant pleural effusion (MPE) and 23 patients with tuberculosis. Data were correlated with the efficacy of MPE control and patient survival. The level of MCP-1 in PE was significantly higher in patients with lung adenocarcinoma than those with tuberculosis. By contrast, the levels of TNF-α and IL-6 were significantly lower in patients with lung adenocarcinoma than those with tuberculosis. An MCP-1 level greater than 3,187 pg/mL (which was used as a cutoff point) indicated failure to control MPE (odds ratio [OR]=2.82, 95% confidence interval [CI]=1.02–7.82, p=0.04). In multivariate analysis, MCP-1 was confirmed as an independent prognostic factor for progression-free survival (hazard ratio [HR]=2.02, 95% CI=1.24–3.30, p=0.01). The level of MCP-1 in PE appears to be a reliable surrogate marker for evaluating the therapeutic efficacy in the control of MPE and predicting survival in lung adenocarcinoma patients with MPE. |
Databáze: | OpenAIRE |
Externí odkaz: |